FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
Investors might want to bet on Cartesian Therapeutics, Inc. (RNAC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Cartesian Growth Corporation III focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Chart does not reflect overnight price.
IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...
Package for generic cartesian control of floating base robots. It includes a ROS-based front end, as well as a programmatic API that can be used inside a real-time loop.
Abstract: The development of wireless communication technology has completely changed the way people communicate, from relying on fixed telephone lines in the past to today's anytime and anywhere ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results